Related Experiment Videos
[Anticoagulant therapy in patients with dilated cardiomyopathy]
1U.O. Clinica Medica Generale e Cardiologia, Università degli Studi di Firenze.
Insights
Patients with heart failure from dilated cardiomyopathy face a high risk of thromboembolism. Anticoagulant therapy is recommended for women with low ejection fraction and all patients with atrial fibrillation.
Area of Science:
- Cardiology
- Thrombosis
- Heart Failure Research
Context:
- Dilated cardiomyopathy (DCM) significantly elevates thromboembolic risk.
- Current evidence for anticoagulation in DCM with sinus rhythm is limited, despite higher risk compared to ischemic cardiomyopathy.
- Specific patient subgroups, like women with low ejection fraction, have clearer indications for anticoagulation.
Purpose:
- To review the current evidence and guidelines for anticoagulant use in heart failure patients with dilated cardiomyopathy.
- To identify patient populations within DCM who benefit most from anticoagulant therapy.
- To discuss therapeutic challenges in patients with intraventricular thrombi.
Summary:
- Heart failure due to DCM carries a 2.0-2.5% annual thromboembolic event rate.
- Anticoagulation is strongly indicated for DCM patients with atrial fibrillation (target INR 2.0-3.0) and women with left ventricular ejection fraction < 25%.
- Evidence supporting anticoagulation for intraventricular thrombi is weak, particularly for flat thrombi; therapy may be reserved for pedunculated or floating thrombi.
Impact:
- Provides guidance on anticoagulant use in a high-risk heart failure population.
- Highlights critical subgroups requiring anticoagulation, improving clinical decision-making.
- Addresses the complexities of managing intraventricular thrombi in DCM, guiding future research and treatment strategies.
Abstract:
Heart failure due to dilated cardiomyopathy is associated with a significant increase in risk of thromboembolism. The incidence can be estimated, on the average, at 2.0-2.5 events per 100 patients per year. At this time, in the absence of randomized trials, limited evidence exists to support the use of anticoagulant treatment for patients with heart failure due to dilated cardiomyopathy in sinus rhythm, even if these subjects appear to be at higher risk than those with ischemic cardiomyopathy and comparable degree of left ventricular dysfunction. Women with left ventricular ejection fraction < 25% constitute a remarkable exception to this rule, and anticoagulation is strongly indicated for them. Unless there are contraindications, anticoagulant treatment is mandatory for patients with heart failure and atrial fibrillation. As studies on preventive treatment in atrial fibrillation have indicated, a target International Normalized Ratio between 2.0 and 3.0 seems appropriate. Patients with intraventricular thrombi present a difficult therapeutic challenge inasmuch as no strong evidence exists that anticoagulant treatment significantly decreases the risk of embolization particularly in patients with flat thrombus. Therapy should thus probably be limited to patients with pedunculated or floating thrombus.